Tips for Pharmaceutical Manufacturing Scale-Up & Tech Transfer

Defining Acceptance Criteria for Site-to-Site Transfer Risks Site-to-site transfer risks in pharmaceutical manufacturing can lead to significant quality issues if not addressed effectively. Understanding how to define acceptance criteria for…

During the transfer process, various symptoms may indicate that risks are materializing. Key signals to monitor include:Click to read the full article.

Symptoms and signals that indicate potential issues during or after a site-to-site transfer can vary widely based on manufacturing processes and regulatory expectations. Here are common signs to monitor:Click to…

The initial indication of a supply gap during the recent site transfer manifested in several forms, including:Click to read the full article.

Identifying symptoms of potential issues during site-to-site transfer is the first step in mitigating risks. Some key symptoms to monitor include:Click to read the full article.

The first step in managing site-to-site transfer risks is recognizing the symptoms or signals that indicate potential problems. Common signals include:Click to read the full article.

During a site transfer, several symptoms may arise that indicate potential risks to product stability. Recognizing these early signals can facilitate prompt actions to mitigate risks.Click to read the full…

Identifying early warning signals is crucial when managing site-to-site transfer risks. Symptoms can manifest in various forms, signifying potential issues in product stability. Here are some of the common signals…

Recognizing symptoms and signals is the first step in managing risks associated with site-to-site transfers. Being vigilant about any anomalies can help in taking timely actions to mitigate issues. Common…

Recognizing the symptoms of potential issues during a site-to-site transfer is crucial for timely interventions. Common signs include:Click to read the full article.

Recognizing early warning signs during site-to-site transfers is crucial to mitigating risks. Symptoms may manifest through unexpected deviations in manufacturing processes, quality control data anomalies, or stakeholder concerns. Common signals…

During routine batch testing and quality assessments, the quality control (QC) team observed deviations in the expected assay results of the biologic therapy. Specifically, the potency of three consecutive production…